In addition, CStone will book revenues from sales of supply to Ewopharma and its affiliates. We believe sugemalimab has a broad application prospect in Europe and global markets. Ewopharma is a reliable pharmaceutical marketing partner with abundant experience and extensive channels in CEE markets. The collaboration will undoubtedly help sugemalimab maximize its clinical and commercial value and benefit more patients in Europe. We look forward to taking a firm step toward the international commercialization of sugemalimab with Ewopharma.
Sugemalimab is an innovative treatment further expanding our oncology franchise and allows us to make an important contribution to health equity in our region. According to Globocan , lung cancer is the third most common cancer in Europe and the leading cause of cancer-related deaths, accounting for one-fifth of all cancer deaths.
Sugemalimab will improve the treatment landscape for patients with advanced non-small cell lung cancer. We are very happy to be able to bring hope and optimism to patients and healthcare professionals alike.
The clinical data of sugemalimab have been presented at various international academic conferences and published in top-tier journals such as The Lancet Oncology, Nature Medicine, Nature Cancer, and Journal of Clinical Oncology.
With more than 60 years presence in the region, Ewopharma has extensive knowledge of these markets and enjoys a privileged position in the area. The company covers all aspects of market access and commercialization of ethical pharmaceutical and consumer health products.
